COVID19 Pipeline 2025: Advancing Global Pandemic Response Strategies

DelveInsight's "COVID-19 Pipeline Insight 2025" report offers extensive analysis on over 180 companies and more than 200 pipeline drugs in the COVID-19 treatment landscape. It features in-depth profiles of COVID-19 pipeline drugs, covering both clinical and nonclinical development phases. Furthermore, it assesses COVID-19 therapeutics by product category, development stage, delivery route, and molecular structure. It also identifies discontinued pipeline products in this domain.

Discover the newest medications and treatment avenues in the COVID-19 Pipeline. Explore DelveInsight's thorough report now! @ COVID-19 Pipeline Outlook

Key Highlights from the COVID-19 Pipeline Report

• On August 27, 2025, CytoDyn Inc. disclosed the launch of a Phase 2b/3 trial to assess the safety and effectiveness of leronlimab (PRO 140) in individuals with severe or critical respiratory symptoms from coronavirus 2019 infection. In this study, participants will be randomly assigned to receive either weekly 700 mg doses of leronlimab (PRO 140) or a placebo. Both leronlimab (PRO 140) and the placebo will be given subcutaneously.

• DelveInsight's COVID-19 Pipeline report showcases a dynamic field with over 180 active contributors developing more than 200 pipeline treatments for COVID-19 care.

• The top COVID-19 Companies include Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma, and others.

• Promising COVID-19 Pipeline Therapies include Calcium Dobesilate, Mannitol, Interferon-Alpha2B, WPV01, ILT101, Ibuzatrelvir, Remdesivir, and others.

Gain insights into COVID-19 clinical trials, emerging treatments, and key companies via DelveInsight @ COVID-19 Treatment Drugs

COVID-19 Emerging Drugs Profile

• DAS181: Ansun Pharm DAS181 is a recombinant sialidase enzyme that functions by stripping sialic acids from lung surfaces, preventing influenza from attaching and infecting. This halts the viral cycle, aiding recovery. By focusing on the host instead of the virus, DAS181 is less prone to resistance from viral mutations, and since it targets the host, it applies to other sialic acid-dependent viruses. DAS181 is administered via nebulization using Aerogen Solo technology. The U.S. Food and Drug Administration (FDA) has awarded Fast Track and Breakthrough Therapy status to DAS181. The drug is currently in Phase III clinical trials for COVID-19 treatment.

• Sarconeos (BIO101): Biophytis Sarconeos (BIO101) is an oral small molecule under development for neuromuscular disorders. From cell and animal studies, it is thought to enhance biological resilience by stimulating the MAS receptor, potentially boosting muscle function and maintaining strength, mobility, and breathing in age-related and wasting conditions. The drug is in Phase III clinical trials for COVID-19.

• MP1032: MetrioPharm MP1032 is a distinctive small molecule that targets overactive immune cell responses by influencing a core metabolic pathway in stimulated immune cells. Mitochondria in these cells ramp up energy production upon activation, producing reactive oxygen species (ROS) and raising intracellular pH. MP1032 activates only in high pH environments, acting as an ROS neutralizer to correct abnormally high ROS levels (oxidative stress). When pH normalizes, the drug deactivates, avoiding interference with essential ROS in other cells, ensuring a strong safety profile. This self-regulating action positions MP1032 as a pioneering anti-inflammatory agent. The drug is in Phase II development for COVID-19.

• GLS-5310: GeneOne Life Science GLS-5310 is a DNA vaccine encoding the spike (S) protein and another SARS-CoV-2 antigen. It is being advanced with backing from the Korean government via the Centers for Disease Control and Prevention as part of a national COVID-19 vaccine initiative. GLS-5310 is in preclinical stages. The drug is in Phase I/II trials for COVID-19.

• S-892216: Shionogi S-892216, created by Sumitomo Pharma, is explored for treating COVID-19-associated acute respiratory distress syndrome (ARDS). As a serotonin 5-HT2A receptor agonist, it seeks to modulate immune responses and curb severe inflammation linked to critical COVID-19 cases. This compound introduces a fresh strategy for managing cytokine storms and enhancing results in seriously ill patients. The drug is in Phase I clinical development for COVID-19.

The COVID-19 Pipeline Report Provides Insights into

• The report delivers comprehensive details on firms advancing therapies for COVID-19, including the cumulative treatments each company is pursuing.

• It reviews diverse therapeutic candidates categorized into initial, intermediate, and advanced development stages for COVID-19 management.

• COVID-19 Companies are focused on precision therapeutics with ongoing and paused (inactive or terminated) programs.

• COVID-19 Drugs in development, sorted by development phase, administration route, target receptor, single or combined therapy, unique action mechanisms, and molecular category.

• Comprehensive examination of partnerships (business alliances and academic ties), licensing arrangements, and funding details to propel future progress in the COVID-19 market.

Explore innovative treatments and clinical trials in the COVID-19 Pipeline. Obtain DelveInsight's detailed report today! @ New COVID-19 Drugs

COVID-19 Companies Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma, and others.

COVID-19 pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

COVID-19 Products have been categorized under various Molecule types such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Learn about emerging COVID-19 drugs, pipeline advancements, and key companies with DelveInsight's expert analysis @ COVID-19 Market Drivers and Barriers

Scope of the COVID-19 Pipeline Report

• Coverage- Global

• COVID-19 Companies- Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma, and others.

• COVID-19 Pipeline Therapies such as Calcium Dobesilate, Mannitol, Interferon-Alpha2B, WPV01, ILT101, Ibuzatrelvir, Remdesivir, and others.

• COVID-19 Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• COVID-19 Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight's comprehensive pipeline report now! @ COVID-19 Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction

2. Executive Summary

3. COVID-19: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Late Stage Products (Phase III)

7. DAS181: Ansun Pharm

8. Drug profiles in the detailed report.....

9. Mid Stage Products (Phase II)

10. MP1032: MetrioPharm

11. Drug profiles in the detailed report.....

12. Early Stage Products (Phase I/II)

13. GLS-5310: GeneOne Life Science

14. Drug profiles in the detailed report.....

15. Preclinical and Discovery Stage Products

16. Drug Name: Company Name

17. Drug profiles in the detailed report.....

18. Inactive Products

19. COVID-19 Key Companies

20. COVID-19 Key Products

21. COVID-19- Unmet Needs

22. COVID-19- Market Drivers and Barriers

23. COVID-19- Future Perspectives and Conclusion

24. COVID-19 Analyst Views

25. COVID-19 Key Companies

26. Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com